Buy Valeant Pharmaceuticals Intl Inc. Now, or You’ll Regret it Later

Valeant Pharmaceuticals Intl Inc.’s (TSX:VRX)(NYSE:VRX) stock rose over 9% following the release of its second-quarter earnings results. Will the rally continue?

| More on:
The Motley Fool

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX), one of the largest specialty pharmaceutical companies in the world, announced better-than-expected second-quarter earnings results before the market opened on July 23, and its stock responded by rising over 9% in the trading session that followed.

Let’s take a closer look at the results to determine if we should consider buying in to this rally, or if we should wait for it to subside.

Surpassing analysts’ expectations with ease

Here’s a summary of Valeant’s second-quarter earnings results compared to what analysts had anticipated and its results in the same period a year ago.

Metric Reported Expected Year-Ago
Adjusted Earnings Per Share $2.56 $2.46 $1.91
Revenue $2.73 billion $2.54 billion $2.04 billion

Source: Thomson Reuters Corporation

Valeant’s adjusted earnings per share increased 34% and its revenue increased 33.9% compared to the second quarter of fiscal 2014. These very strong results can be primarily attributed to growth in the U.S. market, in which the company’s product sales soared 77.3% to $1.84 billion, driven by the strength in its dermatology, contact lenses, dental, and skin care product categories.

Here’s a quick breakdown of six other notable statistics from the report compared to the year-ago period:

  1. Product revenues increased 35.1% to $2.7 billion
  2. Other revenues decreased 20.4% to $37.4 million
  3. Adjusted net income increased 37.9% to $897.1 million
  4. Operating income decreased 3.8% to $341.5 million
  5. Net cash provided by operating activities increased 9.2% to $410.5 million
  6. Adjusted cash flow from operations increased 54.5% to $772.8 million

Valeant also raised its full-year outlook for fiscal 2015, calling for earnings per share in the range of $11.50-$11.80 and revenue in the range of $10.7 billion-$11.1 billion, compared to its previous outlook of earnings per share in the range of $10.90-$11.20 and revenue in the range of $10.4 billion-$10.6 billion.

Could Valeant’s stock head even higher?

It was a very strong quarter for Valeant, so I think its stock responded correctly by rallying over 9%. I also think the stock could continue higher from here, because it still trades at attractive forward valuations, including just 29.3 times its median earnings per share outlook of $11.65 for fiscal 2015 and only 22 times analysts’ estimated earnings per share of $15.49 for fiscal 2016, both of which are inexpensive compared to the industry average price-to-earnings multiple of 37.1 and its five-year average multiple of 159.6.

I think Valeant’s stock could consistently command a fair multiple of at least 35, which would place its shares upwards of $407 by the conclusion of fiscal 2015 and upwards of $542 by the conclusion of fiscal 2016, representing upside of more than 19% and 58%, respectively, from today’s levels.

With all of the information above in mind, I think Valeant Pharmaceuticals represents one of the best long-term growth opportunities in the market today, so Foolish investors should strongly consider beginning to scale in to positions.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Joseph Solitro has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Is Rising But I’m Worried About This One Thing

Canopy Growth stock is soaring as the legalization effort makes real progress in both Germany and the United States.

Read more »

young woman celebrating a victory while working with mobile phone in the office
Investing

3 Roaring Stocks to Hold for the Next 20 Years

These top TSX stocks are excellent long-term buys, given their multi-year growth potential and solid underlying businesses.

Read more »

Two seniors float in a pool.
Dividend Stocks

TFSA: How to Earn $1,890 in Annual Tax-Free Income

Plunk these investments into your TFSA to earn passive income and avoid the taxman.

Read more »

grow dividends
Investing

Here’s My Top 3 TSX Stocks to Buy Right Now

Even though the TSX has been rising, there are still some good bargains out there. Here are three top compounding…

Read more »

Target. Stand out from the crowd
Investing

Prediction: This Canadian Growth Stock Could Double by 2030

Alimentation Couche-Tard (TSX:ATD) is a top growth stock that could do well over the next six or so years.

Read more »

Businessman holding AI cloud
Tech Stocks

Could Investing $20,000 in Nvidia Make You a Millionaire?

Nvidia stock has made investors millionaires in the last 10 years. Is it too late to invest to become a…

Read more »

Engineers walk through a facility.
Dividend Stocks

1 TSX Stock I Wouldn’t Touch With a 10-Foot Pole

AtkinsRéalis (TSX:ATRL) is one TSX stock I'd never invest in.

Read more »

money cash dividends
Stocks for Beginners

Have $500? 3 Absurdly Cheap Stocks Long-Term Investors Should Buy Right Now

If you're looking for cheap stocks, these three have a huge future ahead of them, all while costing far less…

Read more »